Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Experts say there’s been a rise in young people taking Xanax recreationally in Australia. The drug is usually prescribed to ...

These non-alcoholic beverages include ingredients like nootropics and adaptogens which may boost your mood — without the ...

By one estimate, 68% of Americans consume less than the recommended dietary amount of magnesium. Magnesium is essential for ...

Feeling down? What is on your plate might be playing a bigger role in your mood than you think. Depression is a growing ...

Depression continues to grapple a large proportion of the population. Given the side effects associated with the long-term use of conventional antidepressants, there is a need for novel rapid acting ...

Researchers found spinal disinhibition in people with fibromyalgia, adding new clues about the role of central pain ...

The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to treat these conditions, current medications have several limitations, ...

A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...

The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to treat these conditions ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Company’s strategic focus areas for 2025 at the 43rd Annual J.P. Morgan Healthcare ...

The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...